| Chemotherapy |
Cisplatin (alkylating agent) |
Approved |
T4b and metastatic urothelial carcinoma |
| Doxorubicin hydrochloride (topoisomerase II inhibitor) |
Approved |
Stage IV and recurrent bladder cancer |
| Gemcitabine hydrochloride |
Approved |
Advanced bladder cancer |
| 5-fluoro-2′-deoxcytidine + tetrahydrouridine |
Phase II |
Advanced bladder cancer |
| Eribulin mesylate (E7389) |
Phase I / II |
Locally advanced or metastatic bladder cancer |
| Veliparib / ABT-888 |
Phase I |
Non-resectable or metastatic |
| Romidepsin (histone deacetylase inhibition) |
Phase I |
Advanced urothelial carcinoma |
| Anti-tumor immunity |
rhIL-7 vaccine |
Phase II |
Metastatic urothelial carcinoma |
| DC205-NY-ESO-1 fusion protein vaccine +/− sirolimus |
Phase I |
Metastatic urothelial carcinoma |
| Ad/HER2/Neu dendritic cell vaccine |
Phase I |
T3a and above HER2+ bladder cancer |
| Bacillus Calmette-Guerin + PANVAC |
Phase II |
Non-muscle invasive bladder cancer |
| ALT-801 (IL-2 recombinant fusion protein) post-chemotherapy with cisplatin and gemcitabine |
Phase I / II |
Advanced stage muscle-invasive bladder cancer |
| mTOR inhibitors |
ABI-009 (nab-rapamycin) |
Phase I / II |
Advanced non-muscle invasive bladder cancer |
| Sirolimus, post-chemotherapy with cisplatin and gemcitabine hydrochloride |
Phase I / II |
T2 to T4 tumors |
| Anti-angiogenic therapy |
Cabozantinib |
Phase II |
Advanced stage bladder cancer |
| Bevacizumab, post-chemotherapy with gemcitabine hydrochloride + cisplatin |
Phase III |
Metastatic, unresectable, or locally advanced bladder cancer |
| Lenalidomide, post-chemotherapy with gemcitabine hydrochloride and carboplatin |
Phase I |
Unresectable or metastatic bladder cancer |
| Tyrosine kinase inhibitors |
Afatinib |
Phase II |
Ureteral cancer, stage III, stage IV urothelial carcinoma |
| Dovitinib |
Phase II |
BCG-refactory urothelial carcinoma, FGFR3-mutated urothelial carcinoma |
| Erlotinib |
Phase II |
Stage I, II, III and recurrent urothelial carcinoma |
| Gefitinib |
Phase II (completed) |
Locally advanced and metastatic bladder cancer |
| Pazopanib |
Phase II (completed) |
Locally advanced and metastatic bladder cancer |
| Sorafenib |
Phase II (completed) |
Locally advanced and metastatic bladder cancer |
| Sunitinib |
Phase II |
BCG-refactory bladder cancer |
| HER2 blockade |
Afatinib (targets EGF and HER2) |
Phase II |
Refactory bladder cancer |
| MGAH22, a human chimeric antibody against HER2 |
Phase I |
HER2 positive bladder cancer |
